In Conversation With: Dr Lynn Kirkpatrick, Ensysce Biosciences

Pain killers

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.   

In this episode, Megan Thomas is in conversation with Dr Lynn Kirkpatrick, CEO of Ensysce Biosciences. As we all know, the opioid epidemic is one of the biggest issues in the United States today. As of late, it has been cracked down on to prevent overdosing and abuse of opioids, but it still leaves patients with a need for pain medication. Currently, Ensynsce Biosciences is headed into Phase III clinical trials with a drug that improves the care and safety of patients by preventing the possibility of both abuse and overdose of prescription drugs. Today, CEO Dr Kirkpatrick talks about how they are developing this safer option to opioid pain killers, and how it prevents abuse and overdose.

You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free